An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Biodesix to Participate in Two Upcoming Investor Conferences in September
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Biodesix (NASDAQ: BDSX), a leader in data-driven diagnostic solutions for lung disease, announced CEO Scott Hutton will participate in two investor conferences. The Morgan Stanley 20th Annual Global Healthcare Conference is on September 13, 2022, featuring a fireside chat at 9:10 a.m. ET. The H.C. Wainwright 24th Annual Global Investment Conference runs from September 12-14, 2022. Biodesix specializes in non-invasive tests for lung diseases, leveraging advanced AI technology to provide rapid and accurate diagnostic solutions.
Positive
None.
Negative
None.
BOULDER, Colo.--(BUSINESS WIRE)--
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:
Morgan Stanley 20th Annual Global Healthcare Conference
Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings
Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at www.biodesix.com.
H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 Format: 1x1 meetings
Location: Lotte New York Palace Hotel, New York, NY
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
What is Biodesix's participation in the upcoming investor conferences in September 2022?
Biodesix will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, and the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.
Who is the CEO of Biodesix and what will he discuss at the conferences?
The CEO of Biodesix is Scott Hutton, and he will discuss the company's diagnostic solutions for lung disease at the upcoming investor conferences.
What are Biodesix's key offerings in lung disease diagnostics?
Biodesix specializes in non-invasive diagnostic tests, including Nodify Lung® for nodule risk assessment and IQLung™ for treatment decision support in lung cancer.
Where will the Morgan Stanley 20th Annual Global Healthcare Conference be held?
The Morgan Stanley 20th Annual Global Healthcare Conference will be held at the Sheraton Hotel in New York, NY.
When is the webcast for Biodesix's fireside chat at the Morgan Stanley conference?
The webcast for Biodesix's fireside chat at the Morgan Stanley conference will be available live on September 13, 2022, and can be replayed later on their official website.
